February 20, 2017 7:02 PM ET

Biotechnology

Company Overview of Enumeral Biomedical Holdings, Inc.

Company Overview

Enumeral Biomedical Holdings, Inc., a biopharmaceutical company, engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing two antagonist PD-1 antibodies, ENUM 388D4 and ENUM 288C4 for use in treating cancer. The company is also developing antibody drug candidates for various immunomodulatory protein targets, including TIM-3, LAG-3, OX40, TIGIT, and VISTA. Enumeral Biomedical Holdings, Inc. has collaboration agreements with Merck Sharp & Dohme Corp.; and The University of Texas MD Anderson Cancer Center, as well as a research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was f...

200 CambridgePark Drive

Suite 2000

Cambridge, MA 02140

United States

Founded in 2009

Phone:

617-945-9146

Key Executives for Enumeral Biomedical Holdings, Inc.

Enumeral Biomedical Holdings, Inc. does not have any Key Executives recorded.

Enumeral Biomedical Holdings, Inc. Key Developments

Enumeral Biomedical Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter Ended September 30, 2016

Enumeral Biomedical Holdings, Inc. announced unaudited consolidated earnings results for the third quarter ended September 30, 2016. For the quarter, the company reported net loss of $1,260,850 or $0.02 per diluted share compared to net income of $618,284 or $0.01 per diluted share reported in the same period last year. Total revenue was $320,811 against $483,825 reported last year. Loss from operations was $1,518,480 against $2,668,480 reported last year. Net loss before income taxes was $1,260,850 against net income before income taxes of $618,284 reported last year. Net loss for the quarter was primarily due to a decrease of $2,871,515 in the change in the fair value of derivative liabilities and a decrease of $163,014 in revenue, offset by a decrease of $1,313,014 in operating expenses.

Enumeral Biomedical Holdings, Inc. Announces Executive Changes

Enumeral Biomedical Holdings, Inc. announced that Wael Fayad has been appointed Chairman, President, and Chief Executive Officer of the Company, effective as of September 21, 2016. Mr. Fayad brings to Enumeral more than two decades of senior executive and business development experience in the life sciences industry. From 2001 to 2014, Mr. Fayad held positions of increasing responsibility at Forest Laboratories, Inc., most recently as Corporate Vice President, Global Business Development. In that role, he was responsible for business development and alliance management, including the identification, assessment and negotiation of multiple business opportunities. Mr. Fayad helped build and manage a broad network of partnerships at Forest, and upon Forest’s acquisition by Actavis, Mr. Fayad also assisted with the integration of the two companies. In connection with Mr. Fayad’s appointment as Chairman, President, and Chief Executive Officer, John J. Rydzewski stepped down as Enumeral’s Executive Chairman and from the Company’s Board of Directors. Arthur H. Tinkelenberg, Ph.D., Enumeral’s former President and Chief Executive Officer, also stepped down from the Company’s Board of Directors.

Enumeral Biomedical Holdings, Inc. Announces the Resignation of Anhco Nguyen, Ph.D. as Vice President of Research and Development

On August 17, 2016, Anhco Nguyen, Ph.D. resigned from his position as Vice President of Research and Development for Enumeral Biomedical Holdings, Inc.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 29, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Enumeral Biomedical Holdings, Inc., please visit www.enumeral.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.